{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:28:04Z","timestamp":1715988484495},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.bbr.2008.08.041","type":"journal-article","created":{"date-parts":[[2008,9,7]],"date-time":"2008-09-07T17:59:39Z","timestamp":1220810379000},"page":"271-274","source":"Crossref","is-referenced-by-count":8,"title":["Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: Implications for Parkinson\u2019s disease"],"prefix":"10.1016","volume":"195","author":[{"given":"Patrick","family":"Fitzgerald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkady","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony E.","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aideen M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2008.08.041_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ana.20186","article-title":"Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson\u2019s disease","volume":"56","author":"McNaught","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bbr.2008.08.041_bib2","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1002\/mds.21675","article-title":"The pathogenesis of cell death in Parkinson\u2019s disease, 2007","volume":"22","author":"Olanow","year":"2007","journal-title":"Movement Disord"},{"key":"10.1016\/j.bbr.2008.08.041_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","article-title":"Proteasomal function is impaired in substantia nigra in Parkinson\u2019s disease","volume":"297","author":"McNaught","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2008.08.041_bib4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tins.2006.07.006","article-title":"The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases","volume":"29","author":"Zipp","year":"2006","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bbr.2008.08.041_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1196\/annals.1403.002","article-title":"The brain as a target for inflammatory processes and neuroprotective strategies","volume":"1122","author":"Skaper","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.bbr.2008.08.041_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arcmed.2007.10.001","article-title":"Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer\u2019s disease","volume":"39","author":"Rojo","year":"2008","journal-title":"Arch Med Res"},{"key":"10.1016\/j.bbr.2008.08.041_bib7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1460-9568.2007.06018.x","article-title":"Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson\u2019s disease","volume":"27","author":"Crotty","year":"2008","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2008.08.041_bib8","article-title":"The age-related increase in microglial activation in the rat hippocampus is abrogated by a novel phospholipid-based drug formulation","author":"Martin","year":"2005","journal-title":"Soc Neurosci Abstract"},{"key":"10.1016\/j.bbr.2008.08.041_bib9","article-title":"A novel phospholipid-based drug formulation inhibits the age- and LPS-related increases in microglial activation","author":"Martin","year":"2005","journal-title":"Brit Neurosci Assoc Abstract"},{"key":"10.1016\/j.bbr.2008.08.041_bib10","first-page":"910.3","article-title":"A novel phospholipid-based drug formulation inhibits the acute and chronic effects of \u03b2-amyloid administration on long-term potentiation and microglia activation in rat hippocampus","author":"Miller","year":"2005","journal-title":"Soc Neurosci Abstract"},{"key":"10.1016\/j.bbr.2008.08.041_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2008.08.041_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/77060","article-title":"Familial Parkinson disease gene product, Parkin, is a ubiquitin\u2013protein ligase","volume":"25","author":"Shimura","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.bbr.2008.08.041_bib13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1046\/j.1471-4159.2001.00149.x","article-title":"Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult","volume":"76","author":"Lee","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2008.08.041_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/35081564","article-title":"Alpha-synuclein and neurodegenerative diseases","volume":"2","author":"Goedert","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bbr.2008.08.041_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/exnr.2002.8050","article-title":"Altered proteasomal function in sporadic Parkinson\u2019s disease","volume":"179","author":"McNaught","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2008.08.041_bib16","doi-asserted-by":"crossref","first-page":"44405","DOI":"10.1074\/jbc.M308041200","article-title":"Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function","volume":"278","author":"Tofaris","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bbr.2008.08.041_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.12.003","article-title":"Intersecting pathways to neurodegeneration in Parkinson\u2019s disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin\u2013proteasome system","volume":"22","author":"Betarbet","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bbr.2008.08.041_bib18","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1073\/pnas.0409713102","article-title":"Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin\u2013proteasome system and alpha-synuclein","volume":"102","author":"Fornai","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbr.2008.08.041_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s002210100871","article-title":"Procedural motor learning in Parkinson\u2019s disease","volume":"141","author":"Krebs","year":"2001","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.bbr.2008.08.041_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1474-4422(03)00351-X","article-title":"Dementia associated with Parkinson\u2019s disease","volume":"2","author":"Emre","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.bbr.2008.08.041_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.neures.2004.12.006","article-title":"Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson\u2019s disease","volume":"51","author":"Ogura","year":"2005","journal-title":"Neurosci Res"},{"key":"10.1016\/j.bbr.2008.08.041_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2004.02.001","article-title":"Evidence of a protective effect of phosphatidylserine-containing liposomes on lipopolysaccharide-induced impairment of long-term potentiation in the rat hippocampus","volume":"151","author":"Nolan","year":"2004","journal-title":"J Neuroimmunol"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432808005007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432808005007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T03:57:49Z","timestamp":1545796669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432808005007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0166432808005007"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2008.08.041","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}